- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.02. | Year-end report: SciBase | 247 | PR Newswire | STOCKHOLM, Feb. 25, 2025 /PRNewswire/ --
January 1 - December 30, 2024
The fourth quarter in figures
Net sales were TSEK 8,598 (5,764), +49%.The loss after tax was TSEK 17... ► Artikel lesen | |
| 25.02. | SCIBASE: Year-end report | 5 | Cision News | ||
| 21.02. | SciBase: New study shows significant improved clinical accuracy with Nevisense for both US and German dermatologists | 253 | PR Newswire | STOCKHOLM, Feb. 21, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today, that... ► Artikel lesen | |
| 30.01. | SciBase continues US expansion, on-boards Several US Dermatology Practices that Specialize in Skin Cancer Detection | 200 | PR Newswire | STOCKHOLM, Jan. 30, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that... ► Artikel lesen | |
| 28.01. | SciBase: New review article highlights Nevisense effectiveness in identifying malignant skin lesions | 256 | PR Newswire | STOCKHOLM, Jan. 28, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that... ► Artikel lesen | |
| 27.01. | SciBase: Recalculation of warrants of series TO 2 following rights issue | 335 | PR Newswire | STOCKHOLM, Jan. 27, 2025 /PRNewswire/ -- In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April... ► Artikel lesen | |
| 23.01. | SciBase: Nevisense (EIS) included in updated German (S1) imaging guidelines | 375 | PR Newswire | STOCKHOLM, Sweden, Jan. 23, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today... ► Artikel lesen | |
| SCIBASE Aktie jetzt für 0€ handeln | |||||
| 23.01. | SCIBASE: Nevisense (EIS) included in updated German (S1) imaging guidelines. | 2 | Cision News | ||
| 14.01. | SciBase announces final outcome of directed issue and rights issue | 369 | PR Newswire | STOCKHOLM, Jan. 14, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase" or the "Company") today announces the final outcome of the capital raise, consisting of a rights issue of units of approximately... ► Artikel lesen | |
| 13.01. | SciBase announces outcome of directed issue and preliminary outcome of rights issue | 382 | PR Newswire | STOCKHOLM, Jan. 13, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase" or the "Company") today announces the preliminary outcome of the capital raise, consisting of a rights issue of units... ► Artikel lesen | |
| 03.01. | SciBase: The Mayo Clinic, the leading US hospital, will test Nevisense in Pilot | 417 | PR Newswire | STOCKHOLM, Jan. 3, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, announced today that... ► Artikel lesen | |
| 27.12.24 | Today the subscription period in SciBase rights issue begins | 559 | PR Newswire | STOCKHOLM, Dec. 27, 2024 /PRNewswire/ -- Today, on December 27, 2024, is the first day of the subscription period in SciBase Holding AB's ("SciBase" or the "Company") rights issue of units... ► Artikel lesen | |
| 20.12.24 | SciBase letter from the CEO | 452 | PR Newswire | STOCKHOLM, Dec. 20, 2024 /PRNewswire/ -- In 2024, SciBase has advanced its positions significantly and laid the foundation for continued growth, with a new organization in the US, success... ► Artikel lesen | |
| 20.12.24 | SciBase publishes prospectus | 461 | PR Newswire | STOCKHOLM, Dec. 20, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase" or the "Company") announced on November 12, 2024 that the Board of Directors has resolved, subject to the subsequent... ► Artikel lesen | |
| 18.12.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 18.12.2024 | 371 | Xetra Newsboard | Das Instrument 087 GB00BD7XPJ64 NEWRIVER REIT LS-,01 EQUITY wird cum Kapitalmassnahme gehandelt am 18.12.2024 und ex Kapitalmassnahme am 19.12.2024 The instrument 087 GB00BD7XPJ64 NEWRIVER REIT LS-... ► Artikel lesen | |
| 13.12.24 | Bulletin from the extraordinary general meeting in SciBase Holding AB (publ) | 436 | PR Newswire | STOCKHOLM, Dec. 13, 2024 /PRNewswire/ -- Today, an extraordinary general meeting has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance... ► Artikel lesen | |
| 13.11.24 | SciBase Announces Positive Findings in Case Study Monitoring Treatment Outcomes in Atopic Dermatitis Patient | 442 | PR Newswire | STOCKHOLM, Nov. 13, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of artificial intelligence (AI)-based solutions for skin is excited to announce the... ► Artikel lesen | |
| 12.11.24 | Notice to extraordinary general meeting in Scibase Holding AB (publ) | 291 | PR Newswire | STOCKHOLM, Nov. 12, 2024 /PRNewswire/ -- Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to an extraordinary general meeting to be held... ► Artikel lesen | |
| 12.11.24 | SciBase announces collaboration for prediction of atopic dermatitis in infants | 411 | PR Newswire | STOCKHOLM, Nov. 12, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, announced today its... ► Artikel lesen | |
| 12.11.24 | SciBase decides on a directed issue of approximately SEK 22.5 million and a rights issue of up to approximately SEK 59.3 million | 533 | PR Newswire | STOCKHOLM, Nov. 12, 2024 /PRNewswire/ -- The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today decided to carry out a capital raise totaling approximately... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ROKU | 50,50 | 0,00 % | Roku Aktie: Ein aufziehendes Gewitter! | Streaming-Anbieter Roku verliert trotz positiver Analysteneinschätzungen an Börsenwert. Verschärfter Wettbewerb und Sorgen um Werbeeinnahmen belasten die Aktie. Die Roku-Aktie geriet am Freitag deutlich... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,104 | -2,79 % | Sernova Biotherapeutics Inc: Sernova to continue to Cohort C T1D trial in H2 2025 | ||
| BOSTON SCIENTIFIC | 83,50 | +1,83 % | Aktie von Boston Scientific: Kurs nur geringfügig im Minus (93,1910 €) | Der Kurs der der Boston Scientific-Aktie kommt kaum von der Stelle. Der jüngste Kurs betrug 100,54 US-Dollar. Kaum auffällig ist aktuell am Aktienmarkt der Kurs von Boston Scientific. Das Papier liegt... ► Artikel lesen | |
| PAUL HARTMANN | 225,00 | -1,32 % | Paul Hartmann-Aktie // Gute Aussichten bei günstiger Bewertung | Paul Hartmann meldet ein erfolgreiches Geschäftsjahr 2024 und strebt für 2025 weitere Ergebnisverbesserung an. Die Aktie befindet sich in einer charttechnisch reizvollen Situation.
Quelle .. Den vollständigen... ► Artikel lesen | |
| SYSMEX | 16,600 | +1,84 % | EQS-Media: Sysmex Europe SE: Das PA-100 AST-System von Sysmex: Revolutionierung der Diagnose und Behandlung von Harnwegsinfektionen mit Präzision | EQS-Media / 01.04.2025 / 10:08 CET/CEST
Das System verkürzt die Zeit für die Diagnose von Harnwegsinfektionen auf nur 15 Minuten und bestimmt die optimalen Antibiotika innerhalb von 30... ► Artikel lesen | |
| ADDLIFE | 13,590 | -0,80 % | AddLife's Annual Report for 2024 is now published | ||
| EMBECTA | 10,900 | -0,91 % | Embecta Flat on Publication of Diabetes Education Piece | ||
| R1 RCM | 13,400 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.11.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 19.11.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 19.11.2024ISIN NameAU000000SVW5 SEVEN... ► Artikel lesen | |
| ENOVIS | 30,800 | +3,36 % | Enovis Corporation: Enovis Announces Appointment of Damien McDonald as Chief Executive Officer | Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis Corporation... ► Artikel lesen | |
| KANGJI MEDICAL | 0,870 | +8,75 % | KANGJI MEDICAL (09997): FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2024 | ||
| PULMONX | 6,050 | -0,82 % | Pulmonx Corporation: Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results | REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported... ► Artikel lesen | |
| SI-BONE | 11,800 | -4,06 % | SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance | SANTA CLARA, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth... ► Artikel lesen | |
| REVITALIST LIFESTYLE AND WELLNESS | 0,015 | -100,00 % | Revitalist Lifestyle & Wellness Ltd: Revitalist Announces Filing of Audited Financial Statements for the Year-Ended December 31, 2022 and Provides Update on Cease Trade Order | Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) (the "Company") wishes to announce that, further to... ► Artikel lesen | |
| KOOTH | 1,640 | -2,96 % | Kooth PLC - Holding in Company | ||
| PEIJIA MEDICAL | 0,565 | -5,04 % | Peijia Medical Announces 2024 Annual Results | HONG KONG, March 26, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and... ► Artikel lesen |
Das Unternehmen SCIBASE HOLDING AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,016 Euro und damit +3,85 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SCIBASE HOLDING AB finden Sie auf Wallstreet Online.
